Physician profile
Audrey Devine
NPI 1588194039
$3,825.11
in general payments reported to CMS, 2019-2025
17 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $374 · 2023: $1,032 · 2024: $1,113 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.72 |
| Education | $550.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,127.22 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $756.77 | 2022-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $616.68 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Lilly USA, LLC | $305.77 | 2022-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $262.04 | 2023-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $161.00 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $130.86 | 2023-2025 | Strensiq |
| Pfizer INC. | $94.12 | 2023-2025 | |
| Genentech USA, INC. | $93.56 | 2024-2025 | Actemra |
| Ucb, INC. | $70.72 | 2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $64.16 | 2023-2025 | Saphnelo |
| Organon LLC | $36.31 | 2025 | |
| Genzyme Corporation | $27.16 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.77 | 2025 | |
| Sobi, INC | $21.14 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.18 | 2024 | Orencia |
| Biocon Biologics INC | $15.65 | 2024 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.